Dyne Therapeutics Q3 EPS $(0.99) Misses $(0.83) Estimate
Portfolio Pulse from Benzinga Newsdesk
Dyne Therapeutics reported Q3 losses of $0.99 per share, missing the analyst consensus estimate of $0.83 by 19.28%. This represents a 23.75% increase in losses compared to the same period last year.
October 30, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Dyne Therapeutics' Q3 losses were higher than expected, which could negatively impact investor sentiment and the stock price in the short term.
Dyne Therapeutics reported higher than expected losses for Q3. This missed analyst consensus and represents an increase in losses YoY, which could negatively impact investor sentiment and lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100